carbamates has been researched along with Depression, Involutional in 4 studies
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
Excerpt | Relevance | Reference |
---|---|---|
"Depressed individuals (N=45) with elevated levels of anhedonia were assigned to a 5-week treatment period with ezogabine (900 mg/day; N=21) or placebo (N=24)." | 5.41 | Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. ( Bagiella, E; Bevilacqua, L; Chadha, N; Collins, KA; Corniquel, M; Costi, S; Han, MH; Hoch, M; Iosifescu, DV; Iqbal, T; Jha, MK; Kirkwood, KA; Mathew, SJ; Morris, LS; Murrough, JW; Parides, MK; Pizzagalli, DA; Salas, R; Stern, ER; Swann, AC; Ursu, S; Vo-Le, B; Whitton, A, 2021) |
"We report the case of an 81-year-old woman, suffering from a major depressive episode and incipient Alzheimer disease, whom we treated with ECT without interrupting therapy with the acetylcholinesterase inhibitor (ACHE-I) rivastigmine." | 3.71 | Electroconvulsive therapy in a patient receiving rivastigmine. ( Henn, FA; Lederbogen, F; Sartorius, A; Zink, M, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Costi, S | 2 |
Morris, LS | 2 |
Kirkwood, KA | 1 |
Hoch, M | 1 |
Corniquel, M | 1 |
Vo-Le, B | 1 |
Iqbal, T | 1 |
Chadha, N | 2 |
Pizzagalli, DA | 2 |
Whitton, A | 1 |
Bevilacqua, L | 1 |
Jha, MK | 1 |
Ursu, S | 1 |
Swann, AC | 1 |
Collins, KA | 2 |
Salas, R | 1 |
Bagiella, E | 1 |
Parides, MK | 1 |
Stern, ER | 1 |
Iosifescu, DV | 2 |
Han, MH | 3 |
Mathew, SJ | 1 |
Murrough, JW | 3 |
Tan, A | 1 |
Van Dam, NT | 1 |
Kautz, M | 1 |
Whitton, AE | 1 |
Friedman, AK | 2 |
Ahle, G | 1 |
Do, B | 1 |
Nestler, EJ | 1 |
Juarez, B | 1 |
Ku, SM | 1 |
Zhang, H | 1 |
Calizo, RC | 1 |
Walsh, JJ | 1 |
Chaudhury, D | 1 |
Zhang, S | 1 |
Hawkins, A | 1 |
Dietz, DM | 1 |
Ribadeneira, M | 1 |
Wong, EH | 1 |
Neve, RL | 1 |
Zink, M | 1 |
Sartorius, A | 1 |
Lederbogen, F | 1 |
Henn, FA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Developing Neuronal KCNQ Channel Modulators for Mood Disorders[NCT03043560] | Phase 2 | 45 participants (Actual) | Interventional | 2017-09-25 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
A measure specifically designed to assess hedonic capacity for social and interpersonal pleasure.The ACIPS is a 17-item self-report measure scored on a likert scale, ranging from 1 (very false for me) to 6 (very true for me). Full scale from 17-102, higher score indicates higher hedonic capacity (NCT03043560)
Timeframe: baseline and 5 weeks
Intervention | score on a scale (Mean) | |
---|---|---|
baseline | 5 weeks | |
Ezogabine | 46.1 | 65.1 |
Placebo | 53.7 | 59 |
"The SHAPS is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with strongly agree are coded as 1, while a strongly disagree response was assigned a score of 4. Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia." (NCT03043560)
Timeframe: baseline and 5 weeks
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | 5 weeks | |
Ezogabine | 38.7 | 27.5 |
Placebo | 33.7 | 30 |
"change in activation during reward anticipation within the bilateral VS from baseline (Study Visit 0) to the primary outcome visit (Study Visit 5) as measured by functional MRI during the incentive flanker task (IFT). The IFT, like the Monetary Incentive Delay task, permits discrete modeling of brain activity during anticipation of an incentive.~Functional scans were preprocessed and denoised for motion and physiological noise using multi-echo independent component analysis (ME-ICA). Task-based modeling was conducted using AFNI and FSL software. The primary outcome for reward anticipation was the contrast of reward cue compared to neutral cue (reward>neutral cue). The primary imaging outcome was analyzed using a linear mixed model with a single random intercept term treating time as discrete or continuous as appropriate." (NCT03043560)
Timeframe: baseline and 5 weeks
Intervention | Bold Oxygen-level Dependent (BOLD) Signa (Mean) | |
---|---|---|
baseline | 5 weeks | |
Ezogabine | -0.26 | 0.176 |
Placebo | 0.95 | 0.015 |
A widely administered clinician rated global measure of the degree of improvement from the initial assessment in subject overall illness severity. 7 point scale rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT03043560)
Timeframe: baseline and 5 weeks
Intervention | score on a scale (Mean) | |
---|---|---|
baseline | 5 weeks | |
Ezogabine | 4 | 2.1 |
Placebo | 4 | 2.8 |
Clinician rated global measure of subject overall illness severity. a 7-point scale rated as 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. (NCT03043560)
Timeframe: baseline and 5 weeks
Intervention | score on a scale (Mean) | |
---|---|---|
baseline | 5 weeks | |
Ezogabine | 4.4 | 2.6 |
Placebo | 4.6 | 3.3 |
A 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). (NCT03043560)
Timeframe: baseline and 5 weeks
Intervention | score on a scale (Mean) | |
---|---|---|
baseline | 5 weeks | |
Ezogabine | 28.3 | 12.7 |
Placebo | 26.8 | 18.5 |
The SLIPS is a recently developed and validated measure of anhedonia that is tailored to detect recent changes in anhedonia. A 23-item measure, each item range from 0-3. Full scale from 0 to 69, higher score indicates more recent changes. (NCT03043560)
Timeframe: baseline 5 weeks
Intervention | score on a scale (Mean) | |
---|---|---|
baseline | 5 weeks | |
Ezogabine | 32.3 | 16.3 |
Placebo | 28.8 | 21.5 |
The TEPS is composed of 18-items rated on a likert-type scale ranging from 1 (Very True for me) to 6 (Very False for me), and yields two subscales. Ten items make up the TEPS-Anticipatory Pleasure (TEPS-ANT) scale with a range from 10 (not motivated) to 60 (highly motivated). The other eight TEPS items make up the TEPS-Consummatory Pleasure (TEPS-CON) scale; range from 8 (not responsive) to 48 (highly responsive). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia. (NCT03043560)
Timeframe: baseline and 5 weeks
Intervention | score on a scale (Mean) | |||
---|---|---|---|---|
TEPS-ANT baseline | TEPS-ANT 5 weeks | TEPS-CON baseline | TEPS-CON 5 weeks | |
Ezogabine | 26.3 | 37.3 | 24.8 | 32.2 |
Placebo | 28.6 | 32.4 | 25.6 | 29.9 |
A 12-item generic assessment instrument that measures the level of functioning. Each item is scored from 0 to 4 and the items are summed to provide a total score. The score therefore ranges from 0 to 48, with higher scores indicating greater disability. (NCT03043560)
Timeframe: baseline and 5 weeks
Intervention | score on a scale (Mean) | |
---|---|---|
baseline | 5 weeks | |
Ezogabine | 15.5 | 10.2 |
Placebo | 16.5 | 11.6 |
2 trials available for carbamates and Depression, Involutional
Article | Year |
---|---|
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
Topics: Adult; Anhedonia; Carbamates; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; | 2021 |
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.
Topics: Carbamates; Depressive Disorder, Major; Female; Humans; Ion Channel Gating; KCNQ Potassium Channels; | 2020 |
2 other studies available for carbamates and Depression, Involutional
Article | Year |
---|---|
KCNQ channel openers reverse depressive symptoms via an active resilience mechanism.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Behavior, Animal; Carbamates; Depressive | 2016 |
Electroconvulsive therapy in a patient receiving rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Depressive Disord | 2002 |